Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- Jeuveau is an FDA-approved neuromodulator (prabotulinumtoxinA-xvfs) that relaxes facial muscles to smooth glabellar frown lines. Most patients notice results in 2–3 days, and effects commonly last around 3–4 months.1
- Clinical trials show Jeuveau performs similarly to Botox for frown lines, with comparable safety and a modestly faster onset.1 Both are dosed at a 1:1 ratio, and Jeuveau usually carries a lower per-unit price.
- Each neuromodulator has a niche. Dysport spreads more broadly for larger areas, Xeomin offers a “naked” toxin option for patients concerned about resistance, and Daxxify provides the longest median duration at about six months, with a higher upfront cost.1
- Jeuveau was never banned. A 2020 import restriction came from a trade dispute, not from safety issues, and Jeuveau remains fully FDA-approved and widely used across the U.S.
- At Mirror Plastic Surgery, board-certified plastic surgeon Dr. Akash Chandawarkar personally performs every injection using all five major brands and recommends the product that best fits your anatomy and goals.
What Jeuveau Is And How It Works
Jeuveau’s active ingredient, prabotulinumtoxinA-xvfs, works by cleaving the SNAP-25 protein to inhibit presynaptic acetylcholine vesicle fusion at the neuromuscular junction. This temporarily stops the muscle contractions that create glabellar lines, the vertical “11” lines between the eyebrows. It is the first botulinum toxin approved specifically and exclusively for aesthetic use, with no therapeutic indications.
Key fast facts about Jeuveau:
- FDA Approval: February 1, 2019 (BLA 761085, label revised April 2023)
- Manufacturer: Daewoong Pharmaceutical; commercialized in the U.S. by Evolus
- Approved Indication: Moderate to severe glabellar lines in adults
- Typical Glabellar Dose: 20 units across 5 injection sites (4 units each)
- Onset: Initial softening in about 2–3 days, with peak effect at approximately 10–14 days1
- Duration: In clinical practice, Jeuveau’s effects usually last around 3–4 months.1 The FDA label does not state a specific duration and instead establishes a 3‑month retreatment interval with a Day 30 efficacy endpoint.
- Common Side Effects: The most common adverse reactions in trials were headache (12%), eyelid ptosis (2%), upper respiratory tract infection (3%), and increased white blood cell count (1%). Local injection-site pain, swelling, and bruising can occur, though specific rates are not listed in the prescribing information.
- Off-Label Use: All facial areas beyond the glabella are off-label, similar to Dysport, Xeomin, and Daxxify.
Jeuveau Vs. Botox: The Head-To-Head Comparison
Jeuveau and Botox are the closest neuromodulator “twins” on the market. Both are roughly 900 kDa accessory-protein-complex botulinum toxin type A formulations stabilized with human serum albumin. They are dosed at a 1:1 ratio and have similar onset and duration in real-world use.
The pivotal EV-001 and EV-002 phase 3 trials showed clear efficacy of Jeuveau versus placebo, while the EVB-003 phase 3 trial demonstrated non-inferiority of Jeuveau to onabotulinumtoxinA (Botox). In practice, this means the two products deliver comparable results for glabellar lines.
Botox has been FDA-approved for cosmetic use since 2002 and also carries approvals for crow’s feet, forehead lines, and several therapeutic indications such as chronic migraine. Jeuveau, approved in 2019, focuses solely on cosmetic treatment. Jeuveau often shows a modestly faster onset, with most patients noticing softening at 2–3 days versus 3–5 days (and sometimes up to 7 days) for Botox, although both reach peak effect around 10–14 days.1 Jeuveau is also generally priced 20–30% lower per unit than Botox, with some sources citing a 10–30% range, which positions it as a strong value option without sacrificing potency or quality.
To see how Jeuveau and Botox compare across key attributes, and how Dysport and Xeomin fit into the picture, the table below summarizes the main differences at a glance.
| Attribute | Jeuveau | Botox | Dysport | Xeomin |
|---|---|---|---|---|
| Active Ingredient | prabotulinumtoxinA-xvfs | onabotulinumtoxinA | abobotulinumtoxinA | incobotulinumtoxinA |
| FDA Approval (Aesthetic) | 2019 (glabellar lines) | 2002 (glabellar), later expanded to forehead and crow’s feet | 2009 (glabellar lines) | 2011 (glabellar lines) |
| Typical Onset | 2–3 days | 3–7 days | 2–3 days | 3–7 days |
| Typical Duration | Around 3–4 months1 | Around 3–4 months | Around 3–4 months | Around 3–4 months |
| Typical Glabellar Dose (Units) | 20 units | 20 units | About 50 units (2.5:1 ratio) | 20 units (1:1 ratio) |
| Common Side Effects | Injection site pain, bruising, headache, swelling | Injection site pain, bruising, headache, swelling | Injection site pain, bruising, headache, with slightly higher reported rates | Injection site pain, bruising, headache |
Jeuveau Vs. Dysport, Xeomin, And Daxxify: How They Compare
All four products block nerve signals to relax targeted muscles, yet they behave differently in ways that guide which one a skilled injector chooses for each area.
Dysport (abobotulinumtoxinA） tends to diffuse more broadly than Botox or Jeuveau, which can help when treating larger areas such as the forehead. However, a 2023 study in Plastic and Reconstructive Surgery – Global Open found that abobotulinumtoxinA was preferred for wider treatment zones, while onabotulinumtoxinA and prabotulinumtoxinA were preferred for precise areas like the glabella and lateral canthal lines to limit side effects from wider spread. Dysport usually requires about 2.5 times more units than Botox or Jeuveau for a similar effect, so per-unit prices do not tell the full cost story.
Xeomin (incobotulinumtoxinA) contains no complexing proteins and is often called the “naked” toxin. Some providers choose Xeomin for patients who may be developing antibody-mediated resistance, since the lack of accessory proteins may reduce immunogenicity risk. In everyday practice, Xeomin and Jeuveau are commonly dosed at a 1:1 ratio with Botox, although labels state that units are not interchangeable.
Daxxify (daxibotulinumtoxinA) stands out for its longevity. The ASPEN-1 phase 3 trial reported a median duration of 24.0 weeks for the 125-unit dose, which is roughly twice the 12–14 week retreatment interval common with other brands. Daxxify uses a peptide stabilizer instead of human serum albumin, so it contains no human or animal byproducts. Its longer duration appeals to patients who want fewer yearly visits, although each session typically costs more.
Is Jeuveau As Good As Botox, And Is It Safe?
Clinical data support Jeuveau as comparable to Botox in both efficacy and safety for glabellar lines. In the pivotal Phase III trials EV-001 and EV-002, Jeuveau achieved responder rates of 67% and 71%, respectively, for a two-grade or greater improvement in glabellar line severity at Day 30, averaging about 69%.1 The BLOSSOM comparative study confirmed non-inferiority to onabotulinumtoxinA.
Clarifying the “Jeuveau banned” myth: Jeuveau has never been banned by the FDA and has not been withdrawn from the U.S. market for safety reasons. In December 2020, the U.S. International Trade Commission issued a 21‑month import restriction on Jeuveau related to a trade secret dispute between Daewoong and Medytox. The restriction did not reflect safety or efficacy concerns and ended after a three-way settlement among Evolus, Medytox, and Allergan. Jeuveau remains fully FDA-approved and widely used in the United States.
The most common side effects are mild and temporary. They include injection site pain, bruising, headache, and swelling. Eyelid ptosis is rare but recognized, occurring in about 2% of subjects in Jeuveau’s clinical trials. Like all botulinum toxin products, Jeuveau carries an FDA boxed warning about distant spread of toxin effect. In 2009, the FDA required boxed warnings for all approved botulinum toxin products, including Botox, Botox Cosmetic, Myobloc, and Dysport. For BOTOX Cosmetic used at labeled cosmetic facial doses, no definitive serious adverse event reports of distant spread of toxin effect have been reported. Once you feel comfortable with Jeuveau’s safety and performance, the next practical question is cost.
Cost And Value: What To Expect With Jeuveau Pricing
Jeuveau is generally positioned as a value-priced alternative to Botox. Its per-unit price is typically 20–30% lower, although at times the list price has been similar to or slightly higher than Botox, and real savings vary by provider and promotions. Because Jeuveau and Botox use a 1:1 dose for glabellar lines, any per-unit savings usually translate directly into per-session savings.
Cost at Mirror Plastic Surgery is set during a personalized consultation that focuses on using the right amount of the right product for your anatomy. A low per-unit price loses value if the injector uses more units than necessary or places product imprecisely. Correcting a poor result costs the same regardless of brand.
Schedule your personalized consultation to discuss your treatment goals and receive a clear, customized cost estimate.
While brand choice affects details like onset, spread, and duration, the person performing your injections has the greatest impact on your outcome.
The Real Difference: Why Injector Expertise Matters Most
Every neuromodulator in this guide is a tool, and results depend on how your injector uses that tool. A drooping eyelid usually means product was placed too close to the orbital rim, allowing migration to the levator muscle. A frozen forehead usually results from over-treating the frontalis, which removes the brow’s only elevator. Both complications are uncommon when a skilled injector plans dosing and placement carefully. These problems stem from injector technique, not from the product itself.
At Mirror Plastic Surgery, Dr. Akash Chandawarkar brings a plastic surgeon’s command of facial and subdermal anatomy to every injection. He is Harvard-educated, Johns Hopkins-trained, fellowship-trained in aesthetic surgery at the Manhattan Eye Ear & Throat Hospital, and has additional medical innovation training at Stanford University. He is board-certified by the American Board of Plastic Surgery and personally performs all neuromodulator treatments, without delegating injections to a nurse or technician.
The practice’s concierge model allows consultations of up to an hour. This time supports a thorough top-to-bottom facial assessment, a candid discussion of what each product can and cannot achieve, and a plan tailored to your anatomy rather than a preset menu. Many patients appreciate that Dr. Chandawarkar often advises waiting on expensive treatments until they are truly beneficial, which builds long-term trust.
Mirror Plastic Surgery offers all five major neuromodulator brands and selects among them based solely on your goals and facial structure. This supplier-neutral approach supports unbiased recommendations and personalized care.
Frequently Asked Questions
Does Jeuveau Wear Off Faster Than Botox?
Jeuveau and Botox show similar duration in clinical studies, with most patients returning for retreatment every 12–16 weeks.1 Neither product consistently outlasts the other in head-to-head data. Individual variation in duration is common and depends more on metabolism, muscle mass, and injection technique than on brand.
Is Jeuveau Better Than Dysport?
Jeuveau and Dysport each have strengths. Dysport’s broader diffusion can suit larger areas like the forehead, while Jeuveau follows the same 1:1 dosing convention as Botox, which simplifies unit comparisons. Dysport typically needs about 2.5 times more units per area, so a lower per-unit price does not always mean a lower total session cost. The right choice depends on your anatomy, treatment area, and your provider’s clinical judgment.
How Long Does Jeuveau Last?
As noted earlier, Jeuveau usually lasts around 3–4 months for glabellar line treatment,1 and the FDA label advises retreatment no more often than every three months. Some patients fall at the shorter or longer end of that range based on muscle activity, metabolism, and dose. If longer duration is a priority, Daxxify, with a median duration of about six months1, may be worth discussing with your provider.
Can Jeuveau Be Used For Areas Other Than The Glabella?
Jeuveau’s FDA approval covers glabellar lines only. Use in other areas, such as the forehead, crow’s feet, masseters, trapezius, and neck, is considered off-label. Off-label neuromodulator use is common, well-established, and legal when performed by a licensed provider. At Mirror Plastic Surgery, Dr. Chandawarkar treats multiple facial and body areas with neuromodulators based on each patient’s goals, always within evidence-based practice and with full informed consent.
Conclusion: Choosing Your Neuromodulator With Confidence
Jeuveau is a safe, FDA-approved, and clinically effective neuromodulator that compares favorably to Botox in efficacy, safety, onset, and overall performance. The “Jeuveau banned” story stems from a resolved trade dispute rather than a safety concern. Across Jeuveau, Botox, Dysport, Xeomin, and Daxxify, the differences are real yet nuanced, and the best option depends on your anatomy and preferences.
The injector’s expertise ultimately shapes your results. A board-certified plastic surgeon with deep anatomical knowledge, no brand allegiance, and a commitment to honest guidance offers the strongest foundation for natural-looking, long-lasting outcomes.
Get a personalized assessment from Dr. Chandawarkar at Mirror Plastic Surgery and receive a top-to-bottom evaluation from a surgeon who works with every major brand and recommends only what your anatomy truly needs.
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Contact And Location
Mirror Plastic Surgery is located in St. Petersburg, Florida, and serves the greater Tampa Bay area. Reach out by phone, text, or email to schedule your appointment.
- Address: 780 4th Ave S, St. Petersburg, FL 33701
- Phone: 727-361-6515
- Email: hello@mirrorplasticsurgery.com
- Instagram: @mirrorplasticsurgery, @dr.akashplasticsurgery, @perfectlyplastics
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
